Chimerix, Inc. (NASDAQ:CMRX) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET

Company Participants

Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations

Mike Sherman - President and Chief Executive Officer

Allen Melemed - Chief Medical Officer

Mike Andriole - Chief Financial and Business Officer

Josh Allen - Chief Technology Officer

Conference Call Participants

Kevin Strang - Jefferies

Naureen Quibria - Capital One Securities

Ed White - H.C. Wainwright

Troy Langford - TD Cowen

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2023 Earnings Conference Call.

I would now like to introduce you to your host for today's call, Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle LaSpaluto

Thank you. Good morning, everyone, and welcome to the Chimerix First Quarter 2023 Financial and Operating Results Conference Call. This morning, we issued a press release related to our first-quarter operating update. You can access the press release in our Investors section of the Web site. With me on today's call are President [Technical Difficulty] Officer, Allen Melemed; Chief Financial and Business Officer, Mike Andriole; and Chief Technology Officer, Josh Allen. Before we begin, I would like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors. These risks and uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. Please refer to our filings with the SEC for a more complete disclosure of these risks and uncertainties.

At this time, I would like to turn the call over to our President and Chief Executive Officer, Mike Sherman.

Mike Sherman

Good morning, everyone, and thanks for joining. 2023 is definitely off to a good start from an execution standpoint. We continue to open action study sites and now have regulatory approval for the protocol in nine countries. The latest approval was received a few weeks ago from the European Union, and we're activating sites there now. We remain on schedule for our first efficacy analysis in early 2025, which includes an initial overall survival assessment. We are pleased in the meantime to have a strong showing at the American Association for Cancer Research Annual Meeting this year with more than a dozen presentations related to the imipridone platform. Those were presented by the company and our collaborators at Brown University and the University of Michigan. The presentation by Dr. Carl Koschmann from the University of Michigan was the highlight. He presented clinical evidence of ONC201's ability to reverse H3K27 trimethyl loss.